Does differentiation therapy exert antitumor effects on stem-like glioma cells?
Altogether, these results highlight the potential of differentiation treatment to target the stem-like cell population in glioblastoma.
Seropositivity for Cp-HSP60 appears to be a very sensitive and specific marker of ACS, unrelated to Cp IgG antibody titers or hs-CRP and TnT levels. Its causal involvement in instability and its diagnostic role in ACS deserve further study.